Point72 Asset Management L.P. bought a new position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 364,100 shares of the biopharmaceutical company’s stock, valued at approximately $14,269,000. Point72 Asset Management L.P. owned approximately 1.36% of Esperion Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also modified their holdings of the stock. Quantbot Technologies LP boosted its stake in Esperion Therapeutics by 348.6% in the 1st quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,234 shares during the period. Bayesian Capital Management LP acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $231,000. Xact Kapitalforvaltning AB acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $250,000. Virginia Retirement Systems ET AL acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $347,000. Finally, DRW Securities LLC acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $362,000.
In other Esperion Therapeutics news, Director Roger S. Newton sold 7,300 shares of the stock in a transaction that occurred on Friday, August 17th. The shares were sold at an average price of $50.06, for a total value of $365,438.00. Following the completion of the sale, the director now owns 616,426 shares in the company, valued at approximately $30,858,285.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Roger S. Newton sold 17,700 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $51.05, for a total transaction of $903,585.00. Following the completion of the sale, the director now owns 615,726 shares of the company’s stock, valued at approximately $31,432,812.30. The disclosure for this sale can be found here. In the last quarter, insiders acquired 210,000 shares of company stock valued at $8,683,700. Insiders own 32.50% of the company’s stock.
Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.01). During the same period in the prior year, the firm posted ($1.92) EPS. equities research analysts expect that Esperion Therapeutics Inc will post -6.28 EPS for the current fiscal year.
A number of equities analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Esperion Therapeutics in a research note on Friday. They issued a “buy” rating and a $89.00 price objective for the company. Citigroup raised shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $57.00 to $75.00 in a research note on Friday, August 17th. Zacks Investment Research lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Cowen reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Esperion Therapeutics in a research note on Monday, August 6th. Finally, Chardan Capital raised shares of Esperion Therapeutics to a “hold” rating and set a $32.50 price objective for the company in a research note on Friday, July 20th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $80.58.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: Should you buy a closed-end mutual fund?
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.